Serum angiogenin levels predict treatment response in patients with stage IV melanoma

Clinical and Experimental Metastasis

Volumn 24, Issue 7, 2007, Pages 567-574

  Vihinen, Pia ^a   Kallioinen, Minna ^a   Vuoristo, Meri Sisko ^b   Ivaska, Johanna ^c   Syrjänen, Kari J ^a   Hahka Kemppinen, Marjo ^d   Kellokumpu Lehtinen, Pirkko Liisa ^b   Pyrhönen, Seppo O ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Angiogenin; Cytokine array; Melanoma; Prognosis; Survival

Indexed keywords

ALPHA INTERFERON; ANGIOGENIN; BLEOMYCIN; CARBOPLATIN; DACARBAZINE; INTERLEUKIN 2; LOMUSTINE; NAVELBINE; RECOMBINANT ALPHA2B INTERFERON; VINCRISTINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD CHEMISTRY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONCENTRATION (PARAMETERS); DIAGNOSTIC VALUE; DISEASE COURSE; FEMALE; HUMAN; KRUSKAL WALLIS TEST; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIVARIATE ANALYSIS; PREDICTION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; SEX RATIO; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; TUMOR CLASSIFICATION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RIBONUCLEASE, PANCREATIC; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 34948820206     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10585-007-9093-7     Document Type: Article

References (36)

1. Denefle P, Kovarik S, Guitton JD et al (1987) Chemical synthesis of a gene coding for human angiogenin, its expression in Escherichia coli and conversion of the product into its active form. Gene 56(1):61-70
2. Katona TM, Neubauer BL, Iversen PW et al (2005) Elevated expression of angiogenin in prostate cancer and its precursors. Clin Cancer Res 11(23):8358-8363
3. Campo L, Turley H, Han C et al (2005) Angiogenin is up-regulated in the nucleus and cytoplasm in human primary breast carcinoma and is associated with markers of hypoxia but not survival. J Pathol 205(5):585-591
4. Etoh T, Shibuta K, Barnard GF et al (2000) Angiogenin expression in human colorectal cancer: the role of focal macrophage infiltration. Clin Cancer Res 6(9):3545-3551
5. Giles FJ, Vose JM, Do KA et al (2004) Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk Res 28(6):595-604
6. Chao Y, Li CP, Chau GY et al (2003) Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol 10(4):355-362
7. Homer JJ, Greenman J, Stafford ND (2002) Circulating angiogenic cytokines as tumour markers and prognostic factors in head and neck squamous cell carcinoma. Clin Otolaryngol Allied Sci 27(1):32-37
8. Zhao H, Grossman HB, Delclos GL et al (2006) Increased plasma levels of angiogenin and the risk of bladder carcinoma: from initiation to recurrence. Cancer 104(1):30-35
9. Song J, Wang J, Yang J et al (2006) Influence of angiogenin on the growth of A375 human melanoma cells and the expression of basic fibroblast growth factor. Melanoma Res 16(2):119-126
10. Hartmann A, Kunz M, Kostlin S et al (1999) Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. Cancer Res 59(7):1578-1583
11. Ugurel S, Rappl G, Tilgen W et al (2001) Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 19(2):577-583
12. Vuoristo MS, Hahka-Kemppinen M, Parvinen LM et al (2005) Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma. Melanoma Res 15(4):291-296
13. Musolino C, Alonci A, Bellomo G et al (2004) Levels of soluble angiogenin in chronic myeloid malignancies: clinical implications. Eur J Hematol 72(6):416-419
14. Poon RT, Fan ST, Wong J (2001) Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 19(4):1207-1225
15. Verstovsek S, Kantarjian H, Aguayo A et al (2001) Significance of angiogenin plasma concentrations in patients with acute myeloid leukaemia and advanced myelodysplastic syndrome. Br J Haematol 114(2):290-295
16. Shimoyama S, Kaminishi M (2000) Increased angiogenin expression in gastric cancer correlated with cancer progression. J Cancer Res Clin Oncol 126(8):468-474
17. Shimoyama S, Shimizu N, Tsuji E et al (2002) Distribution of angiogenin and its gene message in colorectal cancer patients and their clinical relevance. Anticancer Res 22(2B):1045-1052
18. Harpio R, Einarsson R (2004) S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin Biochem 37(7):512-518
19. Vuoristo MS, Kellokumpu-Lehtinen P, Laine S et al (2000) The value of serum S-100b and interleukins as tumour markers in advanced melanoma. Melanoma Res 10(3):237-241
20. Dlukanovic D, Hofmann U, Sucker A et al (2000) Comparison of S100 and MIA protein as serum marker for malignant melanoma. Anticancer Res 20(3B):2203-2207
21. Vereecken P, Zouaoui Boudjeltia K, Depray C et al (2006) High serum galectin-3 in advanced melanoma: preliminary results. Clin Exp Dermatol 31(1):105-109
22. Kim CJ, Reintgen DS, Balch CM (2002) The new melanoma staging system. Cancer Control 9(1):9-15
23. Ugurel S, Rappl G, Tilgen W et al (2001) Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. Clin Cancer Res 7(5):1282-1286
24. Nikkola J, Vihinen P, Vuoristo MS et al (2005) High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res 11(14):5158-5166
25. Brennecke S, Deichmann M, Naeher H et al (2005) Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma. Melanoma Res 15(6):515-522
26. Cao MG, Auge JM, Molina R et al (2007) Melanoma inhibiting activity protein (MIA) beta-2 microglobulin and lactate dehydrogenase (LDH) in metastatic melanoma. Anticancer Res 27(1B):595-599
27. Reynolds SR, Vergilis IJ, Szarek M et al (2006) Cytoplasmic melanoma-associated antigen (CYT-MAA) serum level in patients with melanoma: a potential marker of response to immunotherapy? Int J Cancer 119(1):157-161
28. Mouawad R, Antoine EC, Gil-Delgado M et al (2002) Serum caspase-1 levels in metastatic melanoma patients: relationship with tumor burden and non-response to biochemotherapy. Melanoma Res 12(4):343-348
29. Fujimoto A, O'Day SJ, Taback B et al (2004) Allelic imbalance on 12q22-23 in serum circulating DNA of melanoma patients predicts disease outcome. Cancer Res 64(12):4085-4088
30. Vonderheide RH, Flaherty KT, Khalil M et al (2007) Clinical activity and immune modulation in cancer patients treated with CP-870, 893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 25(7):876-883
31. Moschos SJ, Edington HD, Land SR et al (2006) Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 24(19):2164-3171
32. Lev DC, Onn A, Melinkova VO et al (2004) Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J Clin Oncol 22(11):2092-2100
33. Caraglia M, Marra M, Pelaia G et al (2005) Alpha-interferon and its effects on signal transduction pathways. J Cell Physiol 202(2):323-335
34. Ugurel S, Rebmann V, Ferrone S et al (2001) Soluble human leukocyte antigen G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer 92(2):369-376
35. Hussein MR (2006) Tumour-associated macrophages and melanoma tumorigenesis: integrating the complexity. Int J Exp Pathol 87(3):163-176
36. Gabrilovich DI, Chen HL, Girgis KR et al (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2(10):1096-1103